The Probable ATP Dependent RNA Helicase DDX58 pipeline drugs market research report outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Probable ATP Dependent RNA Helicase DDX58 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Infectious Disease, and Respiratory which include the indications Melanoma, Unspecified Cancer, Coronavirus Disease 2019 (COVID-19), Hepatitis B, and Viral Respiratory Tract Infection. It also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 targeted therapeutics development with respective active and dormant or discontinued products.
The Probable ATP Dependent RNA Helicase DDX58 pipeline targets constitutes close to 14 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 6, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Probable ATP Dependent RNA Helicase DDX58 overview
RIG-I (retinoic acid-inducible gene 1) is a RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is involved in viral double-stranded (ds) RNA recognition and the regulation of immune response. It acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.
For a complete picture of Probable ATP Dependent RNA Helicase DDX58’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
